Elevar Logo for Common Use.png
Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
March 16, 2023 08:00 ET | Elevar Therapeutics
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Interior photo of Elevar Therapeutics' new corporate headquarters in Fort Lee, New Jersey
Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey
March 07, 2023 09:00 ET | Elevar Therapeutics
FORT LEE, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option
October 11, 2022 16:00 ET | Elevar Therapeutics
SALT LAKE CITY, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 10, 2022 04:00 ET | Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 07, 2022 18:05 ET | Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022
August 25, 2022 07:00 ET | Elevar Therapeutics
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Headshot of Wade Smith, chief financial officer of Elevar Therapeutics
Elevar Therapeutics Names Wade Smith Chief Financial Officer
August 22, 2022 09:01 ET | Elevar Therapeutics
SALT LAKE CITY, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Logo for Common Use.png
Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer
June 28, 2022 14:35 ET | Elevar Therapeutics
SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Logo for Common Use.png
Elevar Therapeutics Shares Results of Phase 2 Rivoceranib Trial in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma
June 06, 2022 17:30 ET | Elevar Therapeutics
CHICAGO, June 06, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have...
Honghui Zhou
Elevar Therapeutics Adds Drs. Honghui Zhou and David Lilienfeld as Vice Presidents
June 02, 2022 14:26 ET | Elevar Therapeutics
Biopharmaceutical company promotes Jennifer Lee to senior vice president of clinical operations, data management and biostatistics SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) -- Elevar...